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Abstract
The purpose of this study was to examine the influence of vitamin D status on
mucosal and systemic immunity and the incidence, severity and duration of upper
respiratory tract illness (URTI) episodes in endurance athletes during a 16-week
winter training period. Blood was collected from 225 subjects at the start of the
study and plasma was analysed for total 25-hydroxy vitamin D (25(OH)D) and
cathelicidin concentration. Blood was also collected at the end of the study and
analysed for 25(OH)D and antigen-stimulated cytokine production. Unstimulated
saliva samples were obtained at the start and at 4-week intervals during the study
period. Saliva samples were analysed for salivary antimicrobial peptides and
proteins (AMPs). Weekly training and daily illness logs were kept. At the start
and end of the study 38% and 55%, respectively, of the athlete cohort had inade-
quate (plasma 25(OH)D 30-50 nmol/L) or deficient (plasma 25(OH)D <30
nmol/L) vitamin D status. There was a significantly higher proportion of subjects
who presented with symptoms of URTI in the vitamin D deficient status group
(initial plasma 25(OH)D <30 nmol/L) during the study period than in the optimal
vitamin D group ( >120 nmol/L) and the total number of URTI symptom days and
the median symptom-severity score in the vitamin D deficient group was signifi-
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cantly higher than in the other groups. The plasma cathelicidin concentration
positively correlated with the plasma 25(OH)D concentration and the saliva
secretory immunoglobulin A (SIgA) secretion rate in the optimal vitamin D status
group was significantly higher than in the other groups. Low vitamin D status
was associated with lower pro-inflammatory cytokine production by monocytes
and lymphocytes. Low vitamin D status could be an important determinant of
URTI risk in endurance athletes and mucosal as well as systemic immunity may
be modified via vitamin D-dependent mechanisms.
Key words: exercise training, cholecalciferol, ergocalciferol, saliva antimicrobial
proteins, common cold
Introduction
It has only recently been recognised that vitamin D plays an important role in up-
regulating immunity [16]. Vitamin D is a key link between Toll-like receptor
(TLR) activation and antimicrobial responses in innate immunity. Vitamin D has
a vital role in up-regulating the expression of antimicrobial peptides and proteins
(AMPs), such as cathelicidin and β-defensin [23]. These AMPs have a broad
range of activities against microorganisms and may be involved in the direct inac-
tivation of viruses [16]. They are produced by epithelial cells and macrophages
and in the lungs are secreted into the biofilm covering the inner surface of the air-
ways, thereby creating a barrier that is chemically lethal to microbes. The biolog-
ically active form of vitamin D (1,25 dihydroxy cholecalciferol) activates the
genes for cathelicidin synthesis and enhances the effectiveness of monocytes and
macrophages in killing microbes by enhancing the oxidative burst potential of
these phagocytic cells [28]. Furthermore, vitamin D has been shown to be essen-
tial in activating and controlling the T-cell antigen receptor and thus enhancing
the recognition of antigens by T lymphocytes [30]. Vitamin D may also influence
cytokine production during periods of infection [3].
Several recent studies have found a negative association between vitamin D status
and respiratory illness incidence in young and elderly adults [1,9,20]. The inci-
dence of respiratory illnesses is generally higher in athletes [10] and low vitamin
D status could be a contributing factor as vitamin D insufficiency has been report-
ed to be common in athletes [21] especially if exposure to natural sunlight is lim-
ited (e.g. when training in the winter months or when training mostly indoors).
During a 4-month winter training period we conducted a study on a large cohort
of endurance athletes who completed daily URTI symptom diaries and reported
weekly training loads using validated questionnaires. We also collected blood
samples from these athletes at the start and end of the study and saliva at the start
and at 4-weekly intervals. Our aims were to determine the influence of vitamin D
status on mucosal immunity, antigen-stimulated cytokine production and the inci-
dence, severity and duration of upper respiratory tract illness (URTI) episodes in
endurance athletes during a winter training period.
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Methods
Subjects
Two hundred and sixty seven subjects who were engaged in regular sports train-
ing (predominantly endurance-based activities such as running, cycling, swim-
ming, triathlon, team games and racquet sports) volunteered to participate in the
study. Subjects ranged from recreationally active to Olympic triathletes and their
self-reported training loads averaged 10 h/week. Subjects were required to com-
plete a comprehensive health-screening questionnaire prior to starting the study
and had not taken any regular medication or antibiotics in the 3 months prior to
the study. All subjects were fully informed about the rationale for the study and of
all experimental procedures to be undertaken. Subjects provided written consent
to participate in the study, which had earlier received the approval of Loughbor-
ough University ethical advisory committee. Subjects were enrolled after having
fulfilled all inclusion criteria, and presenting none of the exclusion criteria (deter-
mined by both questionnaire and interview). Subjects could be included if they
were currently healthy, had been involved in endurance training for at least 2
years, engaged in at least 3 sessions and at least 3 h of total moderate/high-inten-
sity training time per week and were between 18-40 years of age. Subjects repre-
senting one or more of the following criteria were excluded from participation:
smoking or use of any medication, suffering from or had a history of cardiac,
hepatic, renal, pulmonary, neurological, gastrointestinal, haematological or psy-
chiatric illness. A total of 267 healthy individuals (83 females and 184 males)
were recruited as subjects from Loughborough University, UK (latitude 53°N)
during November 2011 with the mean age of the study cohort at recruitment
being 21 ± 3 years (mean ± SD). For the first visit to the laboratory, subjects
arrived in the morning at 08:30-10:30 following an overnight fast of approximate-
ly 12 h and their body mass and height were recorded. Information about the
study was given to them and they then signed an informed consent form. Subjects
then sat quietly for 10 min and completed a health-screening questionnaire and
inclusion/exclusion criteria questionnaire before providing an unstimulated saliva
sample by passive dribble into a pre-weighed sterile collection tube for a timed
period (usually 2 min; longer was allowed if the volume of saliva collected after 2
min was insufficient). After centrifugation for 2 min at 5000 g to remove cells
and insoluble matter, saliva samples were stored frozen at -80ºC prior to analysis.
Subsequently, a resting venous blood sample (12 ml) was obtained by venepunc-
ture from an antecubital forearm vein into two vacutainer tubes (Becton Dickin-
son, Oxford, UK) containing K3EDTA and lithium heparin. Haematological
analysis was immediately carried out on the the EDTA sample (including haemo-
globin, haematocrit and total and differential leukocyte counts) using an automat-
ed cell-counter (Ac.T™5diff haematology analyser, Beckman Coulter, High
Wycombe, UK). Subjects had to have normal haematology to be included in the
study. The remaining EDTA blood was centifuged for 10 min at 1500 g and 4°C
and the plasma stored at -80°C prior to analysis. Heparinised blood was used
immediately for the measurement of antigen-stimulated cytokine production.
Study protocol
During the 4-month study period subjects were requested to continue with their
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normal training programs. Subjects completed a validated health (URTI symp-
toms) questionnaire [14] on a daily basis. Subjects were not required to abstain
from medication when they were suffering from illness symptoms but they were
required, on a weekly basis, to report any unprescribed medications taken, visits
to the doctor or any prescribed medications.
The illness symptoms listed on the questionnaire were: sneezing, headache,
malaise, nasal discharge, nasal obstruction, sore throat, cough, ear ache, hoarse-
ness, fever, chilliness and joint aches and pains. The non-numerical severity rat-
ings of mild, moderate and severe of severity of symptoms were scored as 1, 2 or
3, respectively to provide a quantitative means of data analysis and the total
symptom score for every subject each day was calculated as a sum of multiplied
numbers of symptoms experienced by the numerical severity ratings. A URTI
was deemed present when (i) total symptom score was ≥15 on any two consecu-
tive days and (ii) when a subject positively indicated suffering a common cold on
≥ 3 days according to Jackson et al. [14]. Subjects were also asked to rate the
impact of illness symptoms on their ability to train (above normal, at the same
level, below normal or training stopped). The total number of URTI symptom
days was also determined as the number of days with a symptom score of ≥5
according to Predy et al. [26].
Subjects were also asked to fill in a standard short form of International Physical
Activity Questionnaire (IPAQ; http://www.ipaq.ki.se/downloads.htm) at weekly
intervals, thus providing a quantitative information on training loads in metabolic
equivalents (MET)-h/week [6]. Subjects attended the laboratory every 4 weeks
following an overnight fast. Subjects were required to abstain from any strenuous
physical activity for 24 h before coming to the laboratory. During these visits
body mass was recorded and an unstimulated saliva sample was collected.
Venous blood samples were collected only at the start and end of the study peri-
od. A total of 225 subjects completed the study and provided sufficient blood for
routine haematology and vitamin D status analysis at the start of the study and
sufficient saliva for analysis of AMPs on all 5 occasions. Plasma samples from
181 subjects were also analysed for Vitamin D status at the end of the study. After
vitamin D status analysis of baseline samples, we also analyzed the initial plasma
cathelicidin concentration from a subset of 80 subjects with high-level (all sub-
jects with initial plasma 25(OH)D >90 nmol/L, n=26), a random selection of mid-
level (33-89 nmol/L, n=27) and low-level (all subjects with <33 nmol/L, n=27)
25(OH)D concentration. After vitamin D status analysis of samples collected at
the end of the study, we also measured antigen-stimulated cytokine production in
a subset of 48 subjects with high-level (initial plasma 25(OH)D >90 nmol/L,
n=24 ) and low-level (<30 nmol/L, n=24) 25(OH)D concentration.
Saliva analysis
The saliva volume collected was estimated by weighing and the saliva flow rate
was calculated. Saliva samples were analysed for secretory immunoglobulin A
(SIgA) using an ELISA kit (Salimetrics, Philadelphia, USA) and α-amylase activ-
ity was measured as previously described [22]. Salivary lactoferrin and lysozyme
were analysed using commercially available ELISA kits (Calbiochem, USA and
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Biomedical Technologies, USA, respectively). Secretion rates for each of the
salivary AMPs were calculated as the multiple of the saliva flow rate and the
AMP concentration. Values obtained from the 5 visits at 4-week intervals were
averaged for each subject. All saliva assays were carried out in duplicate. Coeffi-
cients of variation (CVs) for the assays were <5% for all salivary AMPs.
Plasma analysis
Vitamin D occurs in two forms: cholecalciferol (D3) which is formed by the
action of UV light on the skin and ergocalciferol (D2) from plant food sources.
The best measure of vitamin D status is considered to be the sum of the 25-
hydroxy metabolites of D2 and D3 (25(OH)D3 and 25(OH)D2) and the best way
of measuring these is considered to be the high pressure liquid chromatography -
tandem mass spectrometer method [31]. Our EDTA plasma samples were
analysed for 25(OH)D3 and 25(OH)D2 with a high pressure liquid chromatogra-
phy tandem mass spectrometer (Waters Acuity, Manchester, UK) after a maxi-
mum of 10 months in storage with no previous freeze-thaw cycles as described
previously [29]. Briefly, 25(OH)D2, 25(OH)D3 and deuterated internal standard
were extracted from plasma samples, following protein precipitation, using
Isolute C18 solid phase extraction cartridges. Potential interfering compounds
were removed by initial elution with 50% methanol followed by elution of the
vitamins using 10% tetrahydrofuran in acetonitrile. Dried extracts were reconsti-
tuted prior to injection into a high performance liquid chromatography tandem
mass spectrometer in the multiple reaction mode (MRM). The MRM transitions
(m/z) used were 413.2 > 395.3, 401.1 > 383.3 and 407.5 > 107.2 for 25(OH)D2,
25(OH)D3 and hexa-deuterated(OH)D3 (internal standard), respectively. Intra-
assay CVs were <10% across a working range of 2.5–624 nmol/L for both
25(OH)D3 and 25(OH)D2. Measurements were performed in a laboratory meeting
the performance target set by the Vitamin D External Quality Assessment
Scheme (DEQAS) Advisory Panel for 25(OH)D assays.
EDTA plasma was assayed for cathelicidin concentration using a commercially
available ELISA kit (Hycult Biotech, Uden, The Netherlands) according to the
manufacturers’ instructions. The intra-assay CV was 3%.
Antigen-stimulated cytokine production
Stimulated whole blood culture production of cytokines (interferon (IFN)-γ,
tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-2, IL-4, IL-6 and IL-10)
was determined as described previously [11]. The stimulant was a commercially
available multi-antigen vaccine (Pediacel Vaccine, Sanofi Pasteur, UK) contain-
ing diphtheria, tetanus, acellular pertussis, poliomyelitis and haemophilus
influenzae type b antigens. Briefly, 0.25 mL of heparinized whole blood was
added to 0.75 mL of RPMI 1640 medium (Sigma Chemicals, Poole, UK) with an
added 40 µL of Pediacel vaccine cocktail (Sanofi Pasteur msd Limited, Maiden-
head, UK) at a dilution of 1:100, before being incubated at 37°C and 5% CO2 for
24 h. The stimulant dilution of 1:100 used in this study was based on a separate
experiment (unpublished data), which established the dose–response curve for the
measured cytokines over the dilution range of 1:100–1:20 000. Samples were
then centrifuged at 15000 rpm for 4 min at 4°C, following which the supernatant
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fluid was harvested and stored at -80°C prior to analysis of cytokine concentra-
tions using an Evidence Investigator System using the high sensitivity cytokine
biochip array EV3513 (Randox, County Antrim, UK). The intra-assay CV for all
measured cytokines was less than 5.0%. The measured cytokine concentrations
for the monocyte-derived cytokines (TNF-α, IL-1β and IL-6) and lymphocyte-
derived cytokines (IL-2, IL-4 and IFN-γ) were divided by the monocyte and lym-
phocyte counts, respectively to give cytokine production per 106 cells.
Statistical analysis
The Shapiro-Wilk test was used to determine if data sets were normally distrib-
uted. The Kruskal-Wallis test (nonparametric equivalent of one-way ANOVA)
with post-hoc Mann-Whitney test was used to examine differences in the salivary
variables, blood leukocyte counts and the total number of URTI episodes and
symptom days among groups classified by vitamin D status using the following
ranges for plasma total 25(OH)D: 12-30 nmol/L (deficient); 30-50 nmol/L (inad-
equate), 50-120 nmol/L (adequate) and >120 nmol/L (optimal) [4]. For subjects
with URTI symptoms, the symptom-severity score and the duration of URTI
episodes among the 4 groups were also assessed using the Kruskal-Wallis test
with post-hoc Mann-Whitney test. The plasma total 25(OH)D concentrations
were compared between male and female subjects, and indoor and outdoor train-
ing locations using the Mann-Whitney test. The total plasma 25(OH)D concentra-
tions at the start and the end of the study were compared by Wilcoxon signed-
rank test. The difference in proportion of subjects who presented with symptoms
of URTI during the trial between the vitamin D optimal and deficient groups was
assessed by the chi-squared test. Correlation between the number of URTI
episodes and the plasma 25(OH)D concentration as well as the plasma catheli-
cidin and 25(OH)D concentration was done using Spearman's rank correlation
coefficient. One-way ANOVA with post-hoc Bonferroni test was used to exam-
ine differences in the plasma cathelicidin among high, middle and low level vita-
min D status groups. Differences in antigen-stimulated cytokine production
between high and low vitamin D status groups were compared with the Mann-
Whitney test. We also evaluated the impact of URTI episodes on training volume
by comparing physical activity levels (MET-h/week) on weeks when an URTI
episode was present with the average MET-h/week when the subjects were
healthy. Data are presented as mean (±SD) for data sets that were normally dis-
tributed; for data sets that were not normally distributed, the median and
interquartile range (IQR) are shown. The accepted level of significance was
P<0.05.
Results
Adherence to the study
Of the 267 subjects, 239 subjects (169 males, 70 females) completed the full 16
weeks of the study. Reasons for dropout included overseas travel, injury or per-
sistent non-respiratory illness (preventing them from performing training) or due
to undisclosed reasons. Saliva samples were obtained on all 5 visits from 236 sub-
jects. Plasma samples were analysed for total 25(OH)D from 225 subjects
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because there were 11 subjects having insufficient plasma volume for this analy-
sis. At the end of the study blood samples with sufficient volume for analysis of
plasma total 25(OH)D were obtained from 181 subjects.
Baseline characteristics and physical activity levels
Baseline characteristics of the 225 subjects who completed the study and for
whom vitamin D status was established were (mean ± SD) age: 21 ± 3 years,
body mass: 73.4 ± 11.4 kg, height: 176.2 ± 9.1 cm, body mass index: 23.5 ± 2.3
kg/m2 and self-reported weekly training duration: 9.6 ± 5.2 h/week. Analysis of
the IPAQ questionnaires indicated that the training loads were fairly consistent
over the 16 weeks of the study. Mean training loads were 67.5 ± 31.2 MET-
h/week which is equivalent to about 11 ± 5 hours of moderate-vigorous activity
per week.
Vitamin D status
Plasma 25(OH)D2 was below the detection limit (2.5 nmol/L) in 57% of subjects
and the average plasma 25(OH)D2 concentration was only 4.4 nmol/L (median, 0;
IQR, 0-9 nmol/L) . The median
(IQR) plasma 25(OH)D3 concen-
tration at the start of the study was
53 (40-66) nmol/L and the median
total 25(OH)D concentration was
57 (44-71) nmol/L. The number
(and percentage) of subjects
classed as optimal, adequate, inad-
equate and deficient was 11 (5%),
128 (57%), 68 (30%) and 18 (8%).
Plasma 25(OH)D concentration
was not significantly different
(p=0.478) between males (N=157;
median, 56; IQR, 43-69 nmol/l)
and females (N=68; median, 58;
IQR, 45-72 nmol/L). Plasma
25(OH)D concentration was not
significantly different (P = 0.120) between indoor ( N=50; median, 64; IQR, 46-
73 nmol/L) and outdoor sports (N=175; median, 55; IQR, 43-69 nmol/L). The
total plasma 25(OH)D concentration at the end of the study (N=181; median, 47;
IQR, 35-68 nmol/L) was significantly lower (P = 0.003) than that at the start of
the study. At the start of the 4-month study period 38% of athletes had insuffi-
cient or deficient plasma 25(OH)D values (< 50 nmol/L) and by the end of the
study 55% of athletes had plasma 25(OH)D values of less than 50 nmol/L.
URTI symptom incidence and its impact on training loads
Analysis of the URTI symptom questionnaires indicated that 4.0 ± 1.6% of the
cohort experienced a URTI episode each week (Figure 1). One hundred and thirty
six subjects did not experience a single URTI episode during the study period
whereas 103 subjects experienced at least one URTI episode during the study
period.
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Figure 1. Percentage of the cohort reporting a
URTI episode for each week of the study period.
The proportion of subjects whose training was negatively affected when URTI
was present was 70%. When mean MET-h/week physical activity during healthy
(no URTI symptoms) weeks was compared with mean physical activity during
weeks when an URTI episode occurred, there was a significant decrease from
68.3 ± 32.3 to 51.9 ± 40.4 MET-h/week (P = 0.001). Thus, when URTI was pres-
ent subjects reduced their training load by an average of 24%.
Vitamin D status and URTI incidence, severity and duration
The proportion of subjects in the optimal vitamin D status group who experienced
one or more URTI episodes during the trial was significantly lower than for the
vitamin D deficient group (optimal 27%, deficient 67%; P = 0.039). There was a
significant difference for URTI symptom days among the four vitamin D status
groups and the total number of URTI symptom days in the deficient group was
significantly higher than the other groups (Table 1). Vitamin D status tended to
influence prevalence of URTI episodes but this fell just short of statistical signifi-
cance (P = 0.061) and there was a tendency for the deficient group to have more
episodes (Table 1). For subjects who experienced one or more URTI episodes,
there was a significant difference in the median symptom-severity score per
URTI episode among the four groups but no significant difference in the median
duration of episodes (Table 1) although there was a tendency for episodes to be
longer with low vitamin D status. The median symptom-severity score in the defi-
cient group was significantly higher than the other groups.
Plasma cathelicidin concentration
The plasma cathelicidin concentrations were 32.2 ± 11.9, 27.7±10.6 and 24.5±7.5
ng/ml in the high, mid and low level vitamin D status groups, respectively. There
was a significant influence of vitamin D status on the plasma cathelicidin concen-
tration (P = 0.027). The plasma cathelicidin concentration in the high-level vita-
min D status group was significantly higher than in the low-level group (P =
0.023). In addition, there was a positive correlation between the plasma 25(OH)D
and cathelicidin concentrations (r = 0.234, P = 0.036).
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Table 1. Infection symptom incidence among different vitamin D status groups. Also shown are the severity score and duration of URTI 
episodes. 
 
Optimal  Adequate  Inadequate  Deficient  P 
INCIDENCE    N = 11   N = 128  N = 68   N = 18 
 
Number of episodes   0 (0-1) * 0 (0-1)  0 (0-1)   0 (0-1)   0.062 
 
Number of symptom days  1 (0-6)*  4 (0-8)*  4 (1-8)*  9 (3-17)  0.040  
 
Optimal  Adequate  Inadequate  Deficient  P 
WHEN URTI PRESENT  N = 3   N = 56   N = 27   N = 12 
 
Symptom severity score 43 (38-52)* 47 (40-69)* 62 (46-74)* 102 (67-199) 0.013
Duration (days) 5 (5-7)*  8 (6-9)*  8 (5-14)*   13 (10-17)  0.059 
 
Data are median and interquartile range (IQR). P value from Kruskal-Wallis test is shown in right hand column.  
* Significantly different from Deficient (Mann-Whitney U test). 
 
Salivary variables
There was a significant difference in SIgA secretion rate among the four vitamin
D groups (Figure 2) but no significant difference for the other salivary AMPs
(Table 2). The SIgA secretion rate in the optimal vitamin D status group was sig-
nificantly higher than in the other
groups. The SIgA concentration
tended to be lowest in the deficient
group.
Blood leukocyte counts
Based on analysis of blood sam-
ples collected at the start of the
study there was no influence of
vitamin D status on circulating
numbers of total leukocytes, neu-
trophils, lymphocytes or mono-
cytes (Table 3).
Antigen-stimulated cytokine pro-
duction
Both blood monocyte and lympho-
cyte counts were not significantly
different in the subset of subjects
for whom antigen-stimulated
cytokine production was deter-
mined. However, production of all
the monocyte-derived cytokines (TNF-α, IL-1β and IL-6) were significantly
lower in the vitamin D deficient subjects compared with those with high vitamin
D status (all P < 0.005; Figure 3). Production of the lymphocyte-derived pro-
inflammatory cytokine IFN-γ was significantly lower in the vitamin D deficient
subjects compared with those with high vitamin D status (P < 0.01; Figure 4) and
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Table 2. Salivary concentrations and secretion rates of antimicrobial peptides (AMPs) among different vitamin D status groups.  
 
Optimal  Adequate  Inadequate  Deficient  P 
 N = 11   N = 128  N = 68   N = 18 
 
Lactoferrin concentration (ng/mL) 2006 (1413-3184)       2187 (1546-3184) 2491 (1606-3633) 2419 (1624-3001) 0.948 
 
Lactoferrin SR (ng/min)  801 (587-1229) 756 (527-1151) 771 (367-1143) 872 (554-1645) 0.568  
 
Lysozyme concentration (?g/mL) 1524 (641-2595)         1524 (926-2808) 1701 (1102-2693) 1361 (883-2437) 0.687 
 
Lysozyme SR (?g/min)  435 (314-906)  517 (315-872)  504 (315-972)  609 (331-837)  0.970  
 
SIgA concentration (?g/mL)  91 (82-130)                66 (49-100)  76 (46-11 )  59 (46-78)*  0.103 
 
SIgA SR (?g/min)   38.7 (30.3-48.6) 22.9 (14.2-36.6)* 19.5 (12.7-32.3)* 23.6 (14.8-32.9)* 0.018  
 
Amylase activity (U/L)  131 (60-213)               142 (73-233)  131 (74-202)  121 (64-222)  0.839 
 
Data are median and interquartile range (IQR). P value from Kruskal-Wallis test is shown in right hand column. SR = secretion rate. 
* Significantly different from Optimal (Mann-Whitney U test). 
 
1
Figure 2. Influence of vitamin D status on the sali-
va IgA secretion rate. Median values for each
group are indicated by the horizontal lines.
Kruskal-Wallis test indicated a significant influ-
ence of vitamin D status on IgA secretion rate (P =
0.018). Saliva IgA section rate was significantly
higher in the Optimal group than in the other
groups (P < 0.05).
IL-4 also tended to be lower (P = 0.062). Production of IL-2 was not significantly
influenced by vitamin D status. The anti-inflammatory cytokine IL-10 is pro-
duced by both monocytes and lymphocytes so it is not appropriate to normalise its
production by cell counts. The antigen-stimulated production of IL-10 was not
significantly different between the high and deficient vitamin D status groups
(high: median 4.0; IQR 2.4-8.8 pg/ml versus deficient: median 2.8; IQR 2.0-6.0
pg/ml; P = 0.164).
Discussion
This research is of direct relevance to on-going study of the factors that determine
illness susceptibility in athletes. The main findings of the present study were as
follows: (1) there was a higher proportion of subjects who experienced one or
more URTI episodes in the vitamin D deficient status group during the 4-month
study period than in the optimal vitamin D group; (2) the total number of URTI
symptom days and the
median symptom-severity
score in the vitamin D defi-
cient group were signifi-
cantly higher than in the
other groups; (3) the plasma
cathelicidin concentration
was positively associated
with vitamin D status; (4)
the SIgA secretion rate in
the optimal vitamin D status
group was significantly
higher than in the other
groups; (5) pro-inflammato-
ry cytokine production in
response to multi- antigen
stimulation was substantial-
ly lower in vitamin D defi-
cient subjects.
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Table 3. Blood total and differential leukocyte counts among different vitamin D status groups.  
 
Optimal  Adequate  Inadequate  Deficient  P 
 N = 11 N = 128  N = 68   N = 18 
 
Leukocytes (x10
9
cells/L)  5.9 (5.3-6.6)               5.9 (5.2-6.9)                5.9 (5.2-6.9)                6.5 (5.8-7.8)               0.495 
 
Neutrophils (x10
9
cells/L)  2.8 (2.3-3.7)               2.9 (2.4-3.9)                3.0 (2.3-3.5)                3.4 (2.9-4.2)               0.352 
 
Lymphocytes (x10
9
cells/L)  1.9 (1.7-2.3)               2.1 (1.7-2.3)                2.1 (1.8-2.4)                1.9 (1.8-2.0)               0.555 
 
Monocytes (x10
9
cells/L)  0.5 (0.4-0.6)               0.6 (0.5-0.7)                0.6 (0.5-0.7)                0.6 (0.6-0.8)           0.136 
 
Data are median and interquartile range (IQR). P value from Kruskal-Wallis test is shown in right hand column.  
 
Figure 3. Influence of high or deficient vitamin D status on
the antigen-stimulated production of (A) IL-6 and (B) IL-1β
and TNF-α by monocytes. Production of all cytokines
was significantly higher in the high vitamin D status group
compared with the deficient group (all P < 0.005 as indi-
cated by the asterisks).
According to the findings
from the present study, it
seems likely that vitamin D
status has an influence on
URTI symptom incidence.
We found that a higher pro-
portion of subjects (67%) in
the vitamin D deficient sta-
tus group experienced one
or more URTI episodes dur-
ing the 4-month study peri-
od than in the optimal vita-
min D group (27%). Recent
studies have also shown an
inverse association between
vitamin D status and respi-
ratory infection incidence in
young and elderly adults
[1,9]. In the Third National Health and Nutrition Examination Survey involving
18,883 participants [9], it was found that individuals with plasma 25(OH)D con-
centration less than 25 nmol/L had a significantly higher risk of respiratory infec-
tions (24%) than those with 25(OH)D levels higher than 75 nmol/L (17%). In
addition, a population-based study on 6,789 British adults demonstrated that plas-
ma 25(OH)D concentrations are inversely associated with recent URTI [1]. There
was a 7% reduction in the risk of respiratory infections for each 10 nmol/L
increase in plasma 25(OH)D.
Furthermore, we also found that the total number of URTI symptom days in the
vitamin D deficient group was significantly higher than in the other groups.
There was a similar result in a Finnish study in which young male Finnish sol-
diers with plasma 25(OH)D concentration less than 40 nmol/L had more days of
absence from duty due to respiratory infections during the 6-month study period
than soldiers with plasma 25(OH)D concentration more than 40 nmol/L [20]. In
addition, an observational study has shown that adults with 25(OH)D status less
than 95 nmol/L had a longer duration of illness compared with those whose
25(OH)D status was higher than 95 nmol/L [27]. In the present study, it was also
shown that there was a tendency for episodes to be longer with low vitamin D sta-
tus. Moreover, we found that subjects with plasma 25(OH)D higher than 30
nmol/L had less severe symptoms during URTI episodes compared with those
having plasma 25(OH)D below 30 nmol/L. Thus, vitamin D might play a role in
reducing both the severity and duration of URTI symptoms.
There is a plausible mechanism for the inverse association between plasma
25(OH)D status and risk/severity of URTI episodes: vitamin D is a key link
between Toll-like receptor (TLR) activation and antimicrobial responses in innate
immunity. Following activation of the TLR signalling cascade in the presence of
microbes, vitamin D has a vital role in up-regulating the production of AMPs,
such as cathelicidin and β-defensin [23]. These AMPs are produced by both
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Figure 4. Influence of high or deficient vitamin D status on
the antigen-stimulated production of cytokines by lym-
phocytes. * Significant difference between groups ( P <
0.05).
epithelial cells and macrophages and have a broad range of activities against
microorganisms including the direct inactivation of viruses [16]. They are secret-
ed into the biofilm covering the epithelial surface, thereby creating a barrier that
is chemically lethal to microbes. One of these AMPs, cathelicidin, enhances the
microbicidal capability of monocytes and macrophages by increasing the oxida-
tive burst potential of these phagocytic cells [28] and has a defined vitamin D-
dependent mechanism. Pathogenic antigens interact with TLRs on the epithelial
cells and macrophages to upregulate the expression of the 1α-hydroxylase
enzyme that converts 25(OH)D to the biologically active 1,25-dihydroxyvitamin
D. This in turn activates a suite of genes which enhance the production of catheli-
cidin [19,23]. Our finding that the plasma cathelicidin concentration in the high-
level vitamin D status group was significantly higher than in the low-level group
and the significant correlation between plasma 25(OH)D and cathelicidin concen-
trations are in agreement with other studies [2,7,15]. Furthermore, vitamin D has
been shown to be essential in activating and controlling the T-cell antigen recep-
tor and thus enhancing the recognition of antigens by T lymphocytes [30].
A novel and potentially important finding of the present study is that vitamin D
deficiency was associated with a significant and substantially lower production of
pro-inflammatory cytokines by both monocytes and lymphocytes in response to a
multi-antigen challenge. The consequence of this could be an impaired immune
response to an infectious pathogen, increasing the likelihood of an infection
occurring. Our finding is in contrast to other studies that have indicated a reduced
pro-inflammatory cytokine response when the biologically active form of vitamin
D (1,25(OH)2D) is added in concentrations of 10-100 nmol/L to stimulated cul-
tures of peripheral blood mononuclear cells [17,18]. The reason for this discrep-
ancy is unclear. The stimulant we used was a vaccine containing antigens from a
virus and both gram-positive and gram-negative bacteria and we used a whole
blood culture. The studies by Khoo and colleagues [17,18] used lipopolysaccha-
ride or Candida albicans to stimulate isolated peripheral blood mononuclear cells
(PBMC). Inhibition of pro-inflammatory cytokine production in these studies was
only observed when PBMC were incubated with 1,25(OH)2D in concentrations
that were 50-500-fold above the normal healthy range for plasma 1,25(OH)2D
(50-250 pmol/L), so the physiological relevance is questionable. Moreover, the
multiple antigen challenge used in our study provides valuable information on
cytokine production since not all cytokines respond to the same antigen. The
capacity of leukocytes to produce cytokines upon adequate challenge (e.g. with
mitogen, antigen, endotoxin or pathogen exposure) has potentially far reaching
consequences for the entire functional capacity of the immune system. It is highly
likely to reflect the capacity of an individual to defend itself against intruding
microorganisms and hence is a suitable measure to examine the impact of nutri-
tional interventions (e.g., vitamin D supplementation) designed to boost immune
function. We chose to examine whole blood culture rather than isolated PBMC as
the former retains the normal cellular, hormonal and cytokine milieu that the
leukocytes are normally exposed to in the circulation. This model probably comes
closest to the natural environment avoiding artefacts from cell isolation and
preparation and allowing natural interactions between immune components and
antigens within the normal hormonal milieu. Essentially it is an in vitro method of
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simulating responses to an infection. Our findings indicate that low vitamin D status
is associated with an impaired ability to mount a pro-inflammatory cytokine response
to a multi-antigen challenge, whereas the production of anti-inflammatory cytokines
(IL-4 and IL-10) was not significantly influenced by vitamin D status. An impaired
pro-inflammatory response to antigen challenge could increase the risk of succumb-
ing to infection and increase severity and/or duration of symptoms of infection.
Another interesting finding in the present study is that the SIgA secretion rate in
the optimal vitamin D status group was significantly higher than in the other
groups. The mucosal immune system, especially SIgA, functions as the first line
of defence against pathogen invasion by preventing antigens and microbes adher-
ing to mucosal surfaces and interrupting replication of intracellular pathogens
during transcytosis through epithelial cells [10]. Previous studies have shown an
inverse relationship between SIgA values and URTI prevalence. For example,
low SIgA values have been reported to be associated with increased incidence of
URTI in athletes [8,13,24]. The finding in the present study that a significantly
lower proportion of subjects in the vitamin D optimal status group experienced
URTI episodes during the 4-month study period could be explained partially by
the protective effect of their higher SIgA secretion rate. To our knowledge, this is
the first study to report an association between SIgA values and plasma vitamin D
status. It would be interesting to know if high dose Vitamin D supplementation
could elevate SIgA in people with low SIgA secretion.
The inter-individual variation in vitamin D status within our athlete cohort is most
likely due to differences in sunlight exposure rather than diet since the D3 form
(derived primarily from synthesis in the skin) made up >90% of total plasma
25(OH)D. None of the subjects were taking vitamin supplements but we did not
assess dietary vitamin D intake in this study. Vitamin D insufficiency has been
reported to be common in athletes [21] especially if exposure to natural sunlight
is limited (e.g. when training in the winter months or when training mostly
indoors). On the basis of the present data, we found that 38% of athletes had
insufficient plasma 25(OH)D values (< 50 nmol/L) at the start of the 4-month
period and 55% of athletes had plasma 25(OH)D values of less than 50 nmol/L at
the end of the study. This proportion is slightly lower than previously reported in
a study on UK athletes [5] that reported 61% had serum 25(OH)D concentrations
of less than 50 nmol/L during the winter months. Moreover, we also found that
there was a significant drop in plasma 25(OH)D concentration from the start of
the 4-month period to the end of the study. This is most likely due to insufficient
UV radiation of appropriate wavelength between November and March in the UK
(Loughborough latitude is 53°N) to produce vitamin D in the skin [32]. This
probably also explains why there was no difference in plasma 25(OH)D concen-
tration between indoor and outdoor athletes during the winter months in the pres-
ent study, an observation also reported by other studies [5,13]. Given that the
incidence of URTI is generally higher in athletes [10] and that low vitamin D sta-
tus could be a contributing factor, it seems probable that vitamin D supplementa-
tion could be desirable for athletes during the winter months. Our results also
provide confirmation that the presence of URTI episodes in athletes results in a
significant reduction of their training load.
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In conclusion, our study suggests that low vitamin D status could be an important
determinant of URTI risk in endurance athletes. Athletes with low vitamin D sta-
tus may have a higher risk of URTI and suffer more severe symptoms when URTI
is present. This may be due to impaired mucosal and systemic immunity as SIgA
secretion, cathelicidin levels and antigen-stimulated pro-inflammatory cytokine
production appear to be increased by vitamin D-dependent mechanisms. Overall,
with regard to URTI and vitamin D status the results indicate that it is not good to
be deficient in vitamin D (plasma 25(OH)D < 30 nmol/L) and it is probably best
to be optimal (plasma 25(OH)D > 120 nmol/L). Further studies are needed to
establish if vitamin D supplementation can improve immunity and reduce URTI
risk in athletes.
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